Five European countries have agreed to Verona Pharma’s plan to begin enrolling patients in a Phase 2b clinical trial of RPL554 as a maintenance treatment for chronic obstructive pulmonary disease, or COPD. The trial will be conducted in the United Kingdom, Germany, Romania, Bulgaria, and the Czech Republic. Verona expects to start…
News
The United Kingdom’s National Institute for Health and Care Excellence (NICE) recently approved Daxas (roflumilast), developed by AstraZeneca, as a treatment for chronic obstructive pulmonary disease (COPD). The new indication could potentially benefit about 122,000 adults in the U.K. who are estimated to be eligible to receive Daxas, according…
The National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health has granted $10 million to the McDonnell Genome Institute at Washington University to investigate and identify genes associated with chronic obstructive pulmonary disease (COPD) and other lung disorders in people from diverse ethnic backgrounds. Results of…
Recent Posts
- Long-term topical steroid use linked to Cushing syndrome in adolescent
- Getting vaccinated takes a toll on me as someone with Cushing’s disease
- Protein interaction could point to new Cushing’s treatment approach
- Chronic stress from Cushing’s causes long-term memory loss for me
- FDA gives breakthrough status to continuous cortisol monitoring device
- Embracing the power of hope in life with Cushing’s disease
- FDA grants orphan drug status to experimental Cushing’s therapy
- The buffalo hump is one of my least favorite parts of Cushing’s disease
- Simple blood tests may help doctors monitor Cushing’s disease
- Let’s talk about sex and chronic illness